# Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

> **NCT07730632** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- IgAN - IgA Nephropathy
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- C3 Glomerulopathy (C3G)
- Primary Membranous Nephropathy

## Interventions

- **DRUG:** QLS7305 Injection

## Key facts

- **NCT ID:** NCT07730632
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2028-08-10
- **Final completion:** 2028-08-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730632, "Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*